We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aquestive Therapeutics (AQST - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of our Medical group, which includes 1089 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 72.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AQST has returned 89.6% so far this year. At the same time, Medical stocks have lost an average of 10.7%. This means that Aquestive Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Amneal Pharmaceuticals (AMRX - Free Report) . The stock is up 108.5% year-to-date.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aquestive Therapeutics belongs to the Medical - Drugs industry, a group that includes 193 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, this group has lost an average of 15.7% so far this year, meaning that AQST is performing better in terms of year-to-date returns. Amneal Pharmaceuticals is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Aquestive Therapeutics and Amneal Pharmaceuticals. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aquestive Therapeutics (AQST - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of our Medical group, which includes 1089 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 72.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AQST has returned 89.6% so far this year. At the same time, Medical stocks have lost an average of 10.7%. This means that Aquestive Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Amneal Pharmaceuticals (AMRX - Free Report) . The stock is up 108.5% year-to-date.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aquestive Therapeutics belongs to the Medical - Drugs industry, a group that includes 193 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, this group has lost an average of 15.7% so far this year, meaning that AQST is performing better in terms of year-to-date returns. Amneal Pharmaceuticals is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Aquestive Therapeutics and Amneal Pharmaceuticals. These stocks will be looking to continue their solid performance.